Death from Other Causes Among Men with Early-stage Prostate Cancer (08/26/2010)
Among men with early-stage prostate cancer, assessment of other health problems may help guide prostate cancer treatment decisions; men who are likely to die of causes other than prostate cancer may not benefit from aggressive prostate cancer treatment. These findings were published in the Archives of Internal Medicine.

Study Explores Prostate Cancer Among Men with Low PSA Levels (07/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Statins May Reduce Risk of Prostate Cancer Recurrence (07/02/2010)
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.

Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (06/30/2010)
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.

External Beam Radiation Raises Risk of Hip Fracture in Prostate Cancer (06/08/2010)
Men treated with external beam radiation therapy for prostate cancer may have an increased risk of hip fracture, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association.

Statin Use May Lower Risk of Prostate Cancer Recurrence (06/03/2010)
It appears that, among men who have undergone radiation therapy for early prostate cancer, use of statins may lower risk of recurrence, according to a study published in the Journal of Clinical Oncology.

Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (08/09/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.

Study Explores Prostate Cancer Among Men with Low PSA Levels (07/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (06/08/2010)
The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Provenge® for Hormone-refractory Prostate Cancer (08/11/2010)
Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine.

Study Explores Prostate Cancer Among Men with Low PSA Levels (07/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Denosumab More Effective Than Zometa® in Prostate Cancer Patients with Bone Metastases (06/07/2010)
Among men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Study Evaluates Biochemical Recurrence and Mortality in Men with Prostate Cancer (09/09/2010)
A biochemical recurrence refers to an increase in prostate-specific antigen (PSA) after prostate cancer treatment. In a recent study of U.S. veterans, biochemical recurrence was linked with an increased risk of death from prostate cancer. Nevertheless, a majority of men in this population who had a biochemical recurrence did not die of prostate cancer. These findings were recently published in the journal Archives of Internal Medicine.

Jevtana Approved for Hormone-refractory Prostate Cancer (06/21/2010)
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.

Denosumab More Effective Than Zometa® in Prostate Cancer Patients with Bone Metastases (06/07/2010)
Among men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Brothers of Prostate Cancer Patients Undergo More Diagnostic Testing (09/07/2010)
Some of the elevated risk of prostate cancer among those with a family history of the disease may be due to increased prostate cancer testing and detection in this population. These findings were recently published in the Journal of the National Cancer Institute.

Study Evaluates Physician Use of Finasteride for Prostate Cancer Prevention (08/18/2010)
Recent research indicates that 64% of urologists and 80% of primary care physicians surveyed do not prescribe finasteride for prevention of prostate cancer in high-risk men. These findings were recently published in the journal Cancer Epidemiology, Biomarkers & Prevention.

Dogs May Be Able to Smell Prostate Cancer (06/08/2010)
Dogs may be able to smell the presence of prostate cancer in patient urine samples, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association (AUA).